| P2093 | author name string | Robert H Vonderheide | |
| P2860 | cites work | A telomerase component is defective in the human disease dyskeratosis congenita | Q22010917 |
| | hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization | Q24310670 |
| | Extension of life-span by introduction of telomerase into normal human cells | Q24336088 |
| | Human telomerase and its regulation | Q24533247 |
| | Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study | Q24652592 |
| | Cytotoxic T cell immunity against telomerase reverse transcriptase in humans | Q24676613 |
| | Specific Association of Human Telomerase Activity with Immortal Cells and Cancer | Q27860801 |
| | Type, density, and location of immune cells within human colorectal tumors predict clinical outcome | Q28131662 |
| | The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes | Q28139460 |
| | Creation of human tumour cells with defined genetic elements | Q28141602 |
| | Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors | Q28183577 |
| | The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita | Q28189076 |
| | The three Es of cancer immunoediting | Q28251475 |
| | Telomeres shorten during ageing of human fibroblasts | Q29547357 |
| | Telomerase catalytic subunit homologs from fission yeast and human | Q29615387 |
| | Switching and signaling at the telomere | Q29615653 |
| | Telomerase mutations in families with idiopathic pulmonary fibrosis | Q29615671 |
| | Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer | Q29620068 |
| | IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity | Q29620119 |
| | Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction | Q30894063 |
| | Effector memory T cells, early metastasis, and survival in colorectal cancer | Q33992461 |
| | Telomere reduction in human colorectal carcinoma and with ageing | Q34037761 |
| | Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. | Q34155839 |
| | Telomerase activation, cellular immortalization and cancer | Q34235187 |
| | Progress in human tumour immunology and immunotherapy | Q34253585 |
| | From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens | Q34348874 |
| | Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia | Q34409487 |
| | Telomerase as a universal tumor-associated antigen for cancer immunotherapy | Q34535727 |
| | Model predicting survival in stage I melanoma based on tumor progression | Q34669608 |
| | Telomerase: a target for cancer therapeutics | Q34979724 |
| | Tumor-specific shared antigenic peptides recognized by human T cells | Q35005926 |
| | Tumors as elusive targets of T-cell-based active immunotherapy | Q35155955 |
| | High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. | Q35631830 |
| | A listing of human tumor antigens recognized by T cells: March 2004 update | Q35862179 |
| | Decreased tumor surveillance in perforin-deficient mice | Q36367528 |
| | Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. | Q36368332 |
| | Mechanisms of immune evasion by tumors | Q36490750 |
| | Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice | Q36497106 |
| | Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes | Q36633820 |
| | Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase | Q36642248 |
| | Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death | Q36742412 |
| | Telomerase immunity from bench to bedside: round one. | Q36745749 |
| | Identification of a new hTERT-derived HLA-A*0201 restricted, naturally processed CTL epitope. | Q40140237 |
| | Direct vaccination with pseudotype baculovirus expressing murine telomerase induces anti-tumor immunity comparable with RNA-electroporated dendritic cells in a murine glioma model | Q40203059 |
| | In vitro anti-tumor immune response induced by dendritic cells transfected with hTERT recombinant adenovirus | Q40209827 |
| | Immunogenic HLA-B7-restricted peptides of hTRT. | Q40213758 |
| | Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma | Q40275006 |
| | Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses. | Q40278531 |
| | Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer. | Q40357992 |
| | Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells | Q40408896 |
| | Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes | Q40433302 |
| | Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes | Q40622521 |
| | HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy | Q40730426 |
| | Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. | Q40782201 |
| | Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes | Q40811313 |
| | Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. | Q40856900 |
| | Cancer vaccines based on the identification of genes encoding cancer regression antigens | Q41459252 |
| | T cell defined tumor antigens | Q41642406 |
| | Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients | Q41672999 |
| | Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia | Q41809404 |
| | Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells | Q45865490 |
| | Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells | Q45885511 |
| | Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy | Q46535481 |
| | Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications | Q50417083 |
| | Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. | Q51051603 |
| | Inhibition of telomerase limits the growth of human cancer cells. | Q52536487 |
| | Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. | Q53650886 |
| | Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. | Q53988237 |
| | Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. | Q54196124 |
| | Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer | Q56815464 |
| | Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA | Q56967613 |
| | Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients | Q57556467 |
| | A novel peptide-nucleotide dual vaccine of human telomerase reverse transcriptase induces a potent cytotoxic T-cell response in vivo. | Q64988743 |
| | Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo | Q71091026 |
| | A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes | Q73228098 |
| | Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors | Q73773504 |
| | Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma | Q73841959 |
| | Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span | Q74311298 |
| | Identification of serum anti-human telomerase reverse transcriptase (hTERT) auto-antibodies during progression to hepatocellular carcinoma | Q74625029 |
| | Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product | Q74710975 |
| | A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies | Q79261149 |
| | Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21 | Q79820772 |
| | The promise of cancer vaccines | Q80038678 |
| | Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide | Q80548343 |
| | Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope | Q81430192 |
| | Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer | Q81482708 |
| | Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies | Q83365600 |
| P433 | issue | 1 | |
| P304 | page(s) | 173-180 | |
| P577 | publication date | 2007-07-17 | |
| P1433 | published in | Biochimie | Q2904035 |
| P1476 | title | Prospects and challenges of building a cancer vaccine targeting telomerase | |
| P478 | volume | 90 | |